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Abstract 
The focus of this research is on cell migration and how it can be better understood 
through the use of small molecules that modulate cell migratory activity. The results have 
particular relevance in the realm of cancer pharmacology. Cardiac glycosides, which are known 
inhibitors of the eukaryotic Na
+
/K
+
-ATPase, have been determined to have antimigratory 
activities through the screening of several small molecule libraries. Here we investigate the 
antimigratory activities of the cardiac glycoside digitoxin as well as its analogs that we 
synthesized. Antimigratory activity was determined by conducting a wound closure assay with 
MDA-MB-231 human breast carcinoma cells.  This antimigratory activity was compared to the 
inhibitory activity when Na
+
/K
+
-ATPase was treated with digitoxin and its analogs in a Na
+
/K
+
-
ATPase assay.  A coloration between wound closure activity Na
+
/K
+
-ATPase inhibitory activity 
provides evidence that cardiac glycosides inhibit cell migration through their interaction with the 
Na
+
/K
+
-ATPase protein. This research will provide the grounds to study the specific pathways in 
which Na
+
/K
+
-ATPase is linked to the regulation of cell migration. 
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Chapter One: Introduction 
1A. What are cardiac glycosides? 
Cardiac glycosides are a class of naturally occurring small molecules that have been used 
as drugs to treat heart conditions, namely congestive heart failure and cardiac arrhythmias such 
as atrial fibrillation. Recorded medicinal use of cardiac glycosides dates back as far as 1785, 
when Sir William Withering first described using the foxglove plant as a treatment for “dropsy,” 
or edema associated with congestive heart failure.
1,2
 The foxglove plant, Digitalis purpurea, is 
still used as a source for extracts containing the cardiac glycoside digoxin, which has well 
studied inotropic properties that have been shown to increase myocardial contractility.
2
  
Some of the most well known and well studied cardiac glycosides include digoxin, 
digitoxin, ouabain, oleandrin, and bufalin. Although these natural molecules each have their own 
unique chemical structure, they all share a conserved core framework.  
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17 
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Ring 
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        As the name cardiac glycoside implies, each molecule has a glycone or sugar portion. 
The glycone can be a monosaccharide such as the single L-rhamnose on ouabain or it can be a 
polysaccharide chain such as the 2-deoxy trisaccharide of digitoxin. The sugars tend to be the 
part of the chemical structure that has the least significant effects on the biological activities of 
the molecules.  
The glycone portion of the cardiac glycoside can be cleaved by hydrolysis to leave the 
aglycone. The suffix –genin is used to indicate that the structure only includes the aglycone. So 
the aglycone of digitoxin is called digitoxigenin. The aglycone is composed of two important 
regions: the tetracyclic steroidal core, and the lactone on C-17. The steroid moiety consists of 3 
six-membered rings and 1 three-membered ring for a total of four fused rings. The way in which 
these four rings are fused provides them with a three dimensional structure that is very important 
to the overall shape of the entire cardiac glycoside and its biological activity. Rings A and B are 
fused in a cis conformation and rings C and D are also fused in a cis conformation. However, the 
two center rings B and C are fused in trans conformation that gives the steroid core a slight twist 
and a curve into a crescent shape. The level of oxidation of the steroid core with hydroxyl group 
varies among the different cardiac glycosides. In fact, the only difference in the structures of 
digoxin and digitoxin is the hydroxyl group on the C-12 of digoxin. Additional hydroxyl groups 
on the tetracyclic steroidal core can increase the solubility of the molecule.  
The lactone ring in cardiac glycosides is always on C-17 and determines which of two 
groups the cardiac glycoside falls into. If the lactone ring is a butenolide ring, like in ouabain and 
digoxin/digitoxin, then that cardiac glycoside is a cardenolide. If the lactone ring is an α-pyrone 
ring, such as in bufalin, then the molecule is classified as a bufadienolide. While cardenolides are 
extracted as secondary plant metabolites, bufadienolides are often produced by mammals and 
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amphibians as well as plants and are five time as toxic in humans
3
. Overall, bufadienolides are 
the much less common form of cardiac glycosides and due to their higher toxicity, they are not 
used in the same pharmacological capacity as cardenolides. With regard to the biological 
activities of cardenolides glycosides, the butenolide ring is thought to be more important than the 
sugars, but less important than the tetracyclic steroidal core. 
The most well studied biological activity of cardiac glycosides is their interaction with 
the Na
+
/K
+
 ATPase pump, an enzyme found in the plasma membrane of virtually all animal 
cells. This enzyme has four subunits; two α subunits that extend into the interior surface of the 
cell and two ß subunits that extend into the exterior space around the cell. There are different 
isoforms of these subunits that are found in different cells in the body.
4
  Four different isoforms 
of the α subunit (α1, α2, α3, and α4) and three different isoforms of the ß subunit (ß1, ß2, ß3) 
have been discovered
5
 Combinations of these subunits are found throughout different tissues. For 
instance, the α1ß1 isoform is present in all cell types, while the α3ß2 heterodimer isoform is less 
common, and found in the pineal gland and retinal photoreceptor cells.
5
 Although it is agreed 
upon that cardiac glycosides bind to the α subunits of the Na+/K+ ATPase pump, it is difficult to 
say whether cardiac glycosides have stronger affinity to a particular α subunit isoform. Different 
studies have shown ouabain to have greater affinity for each α1, α2, and α3 depending on the 
study and the type of animal tissue used.  
An analysis of a crystal structure of ouabain bound to the Na
+
/K
+
 ATPase pump showed 
how each of the important structures (the lactone ring, the steroidal core, and the carbohydrate 
rhamnose) interact with the transmembrane helices of Na
+
/K
+
 ATPase.
6
 The crystal structure 
agrees that the main binding sites for ouabain are the M5 and M6 helices on the α subunit, but it 
challenges the previously held idea that ouabain binds to the extracellular surface portion of 
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these transmembrane helices.
6
  Instead, the crystal structure (Figure 1) shows that ouabain is 
bound deep within the helices and is held almost entirely within the phospholipid bilayer of the 
membrane.
6
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The inotropic properties of cardiac glycosides are a result of inhibition of Na
+
/K
+
 
ATPase. One of the important physiological functions of this pump is to regulate the ion 
concentrations across the cell’s plasma membrane. As the name implies, the Na+/K+ ATPase 
pump requires phosphorylation by ATP for each ion exchange to occur. The net result of each 
ion exchange is 3 Na
+
 transported out of the cell, 2 K
+
 transported into the cell, and one ATP 
consumed. When the cardiac glycoside binds to the α subunit of Na+/K+ ATPase in the cardiac 
muscle, it stops this Na
+
/K
+
 ion exchange and allows for a greater force and velocity of 
contraction in the heart.
7 
 In order to understand how this mechanism works, it may be helpful to 
briefly describe the normal mechanism of contraction in cardiac muscle. 
Muscle contraction starts with the generation of an action potential, or depolarization of 
the surface of a cell. This action potential is a result of a rapid exchange of ions across the cell 
membrane. Once the action potential is created, there is a release of Ca
2+
 from the sacroplasmic 
reticulum. Ca
2+
 binds to troponin, the regulatory protein in the interaction between actin and 
myosin.
8 
 Actin and myosin will interact and continue to cause muscle contractions until the Ca
2+
 
is no longer present to bind troponin. The cell returns Ca
2+
 levels back to normal by pumping it 
out of the cell in exchange for Na
+
 flowing down its concentration gradient into the cell.
8
  
When cardiac glycosides bind to Na
+
/K
+
 ATPase, they effectively inhibit the exchange of 
Na
+
 and K
-
 ions. This disrupts the concentration gradient of Na
+
, and prevents Na
+
 from flowing 
down its gradient into the cell in exchange for Ca
2+
.
9
 Since there is no way to effectively remove 
Ca
2+
 from the cell, Ca
2+
continues to binds troponin and allow for the interaction of actin and 
myosin. This results in greater force in the contractions of the cardiac muscle.
10 
Although it is most well known for its ion exchange activity, the Na
+
/K
+
 ATPase pump is 
becoming increasingly thought of as an isoenzyme.
5
 Rather than accounting for the activity of 
10 
 
one biological process, it is a critical enzyme for an entire host of critical cell functions. Na
+
/K
+
 
ATPase is responsible for creating the electrochemical gradient across the plasma membrane that 
allows for the secondary transport of various ions, substrates, and neurotransmitters via Na
+
-
coupled transport systems.
5
  The electrochemical gradient created by Na
+
/K
+
 ATPase is also 
critical to renal physiology, as it facilitates the reabsorption of water in the proximal convoluted 
tubules of the nephrons to allow for the maintenance of homeostasis of electrolytes and fluids in 
the body.
5
  The ability of Na
+
/K
+
 ATPase to act as a receptor for a signal transduction pathway is 
also a very important part in its role as an isoenzyme.  
Considering the many functions of Na
+
/K
+
 ATPase, it is not surprising that the interaction 
of cardiac glycosides with Na
+
/K
+
 ATPase effects several cell processes besides its most well 
studied relationship with cardiac muscle contraction. These cell processes include activation of 
cytoplasmic Ca
2+
 oscillation, cell growth, induction of apoptosis, glycogen synthesis, inhibition 
of endocytosed membrane traffic, and the production of high density microtubule granules.
11
 
Some of these effects are a result of cardiac glycosides inhibiting the ion pumping of the 
ATPase. However, more studies are showing that these functions may the result of Na
+
/K
+
 
ATPase acting as a receptor for cardiac glycosides and starting a signal cascade triggered by 
phosphorylation , and not necessarily correlated with the inhibition of the Na
+
/K
+
 ion pumping.
11
  
 
1B. The Importance of Cell Migration 
The ability of cells to migrate is of great physiological significance. Cell migration is 
necessary for many normal cell processes, such as embryogenesis, immunoresponses, and wound 
closure. In normal cells, the inhibition of cell migration would create significant problems in 
growth, development, and maintenance of healthy tissues. However, there are times when the 
11 
 
blocking of cell migration would be beneficial. Inhibiting cell migration could help to obstruct 
diseased states that rely on the movement of cells, including tumor formation, tumor metastasis, 
and vascularization.  
Cell migration is a very complex process involving the components of the cytoskeleton; 
actin, microtubules, and intermediate filaments. Microtubules are the primary facilitators of 
ciliary and flagellar movement and they also interact with actin and create cell polarity in regular 
cell movement.
12
 Intermediate filaments are more important for structural support and they do 
not play as significant of a role in cell movement other than signal transduction.
12
 This leaves 
actin as the primary driving force in the cytoskeleton that allows for cell migration.   
The start of cell migration requires a protrusion of the cell membrane in direction of 
movement. This protrusion is caused by a change in the structure of actin network within the 
cell. The actin network is dynamic and can change as a result of lengthening actin chains by 
polymerization, disassembly of actin filaments into free monomers, crosslinking of actin 
filaments, and restructuring of actin density and organizational geometry.
12
 This dynamic actin 
network begins to change once directionality and polarity has been established along the plane of 
motion. Then the actin polymerizes to form filaments that create a protrusion of the outer 
membrane, called the leading edge, in the direction of migration. Actin polymerization is the 
assembly of free actin monomers (G-actin) into a polar polymer (F-actin). The F-actin is 
considered polar because it has two different ends, a barbed end and a pointed end. The barbed 
end of F-actin is the growing end, because it is easily accessible to rapid polymerization by the 
free G-actin with the help of ATP, Mg
2+
, and a G-actin binding protein.
12
 After polymerization 
of G-actin into F-actin has created a protrusion or leading edge, actin and myosin work together 
to create contractions and provide the force to pull the cell body forward, retract the lagging 
12 
 
portion of the cell, and cause detachment from the substratum.
12
 Integrins also play a very 
important role in attachment and detachment from the substratum. Integrins are surface proteins 
that serve as adhesion receptors for the extracellular matrix.
13
 They are regulated by intracellular 
signaling mechanisms and they also receive extracellular signals which they relay as intracellular 
signals themselves.
13
  
Figure 2 (reproduced with permission)
12
 provides a very basic representation of the 
process of cell migration of animal cells. Although the process may appear simple in the 
diagram, it is actually a very complicated process full of intricate signaling cascades and 
regulatory pathways. With so many different molecules and pathways involved, there are many 
potential targets for inhibition of cell migration. Inhibitors can target either free or polymerized 
actin or even the capping protein that regulates binding to the barbed end of F-actin.
12 
 Inhibitors 
of cell migration can also target other known, important structures such as microtubules or 
integrins. Then there is the host of upstream signaling molecules that all provide targets for the 
inhibition of cell migration.  
Fig. 2. 
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There are remarkably few known small molecule inhibitors of specific proteins that 
regulate cytoskeleton dynamics in cell migration.
12
  Small molecules mimic the much larger 
naturally occurring molecules that regulate cytoskeleton dynamics and act as highly useful tools 
for understanding cell migration. All of the mechanisms by which cells migrate and methods by 
which migration is regulated are still not fully understood
12
, yet cell migration is still certainly an 
appealing target for drugs.  
 
 
1C. Significance to Cancer Pharmacology 
Small molecules that are able to effectively target specific proteins and inhibit cell 
migration would have potential application to cancerous cell invasion, the early stages of 
cancerous tumor development, as well as metastasis. Inhibition of cell invasion and metastasis 
would be particularly useful for controlling the formation of new tumors after unsuccessful 
treatment or surgery. This type of inhibition would also amplify the effectiveness of other anti-
cancer drugs targeting containment of solid tumors by stopping cell growth and division.
14
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1 - Digitoxin 
Chapter Two: Synthesis and characterization of digitoxin analogs 
2A. Purchase and characterization of commercial digitoxin 
 Digitoxin 1 was purchased commercially from Acros Organics (CAS number: 71-63-6) 
and was used as the starting structure for the synthesis of the rest of the digitoxin analogs. 
Digitoxin was soluble in water, methanol, ethyl acetate, and chloroform. In most of the reactions 
with digitoxin, methanol was the solvent used. Ethyl 
acetate was used as part of the solvent system during 
column chromatography to separate reaction products. Both 
deuterated chloroform and deuterated methanol were used 
as solvent for NMR spectroscopy.  
 Characterization of 1 was performed using 
1
H and 
13
C NMR spectroscopy. The observed NMR peak values 
matched those found in the literature.
15
 When synthesizing analogs of 1, these NMR data were 
used for comparison. The emergence of new peaks or the loss of peaks were helpful in 
confirming structural changes. 
 
2B. Synthesis and characterization of digitoxigenin 
 Digitoxigenin 2 is the aglycone of digitoxin, and it was synthesized using two different 
procedures. The first method for synthesizing 2 was an established procedure for the 
deglycosylation of ouabain, a cardiac glycoside very similar in structure to digitoxin.
16
  Hong 
describes the reaction of ouabain octahydrate with acetone-12 N hydrochloric acid (0.4 mL 
HCl/100 mL acetone) at 23°C, with the aglycone forming as a precipitate after 10 days under 
reaction conditions.
16
 As shown by reaction A in scheme 1, we used digitoxin 1 as the starting 
15 
 
material under the same these same reaction conditions for the synthesis of the digitoxin 
aglycone, digitoxigenin 2. The reaction mixture was then separated by column chromatography 
to purify product 2. This procedure that Hong described for the 
 
deglycosylation of ouabain was successful for digitoxin, however the 10 to 14 days required for 
the reaction to reach completion was not ideal. So we switched to a different procedure that also 
used acid catalyzed hydrolysis, but under different reaction conditions allowing for the synthesis 
of 2 in several hours instead of 10 to 14 days.
17
 The reaction conditions described by Pádua are 
shown by reaction B in scheme 1. Under this procedure, 1 was dissolved in methanol and 1M 
aqueous HCl. The solution was then refluxed at 55°C for 35 minutes. The reaction products were 
then extracted with CHCl3 and neutralized with 3% NaHCO3. Product 2 was purified by column 
chromatography.  
 Characterization was performed by 
1
H and 
13
C NMR spectroscopy. The experimental 
peak values matched the peak assignments reported by Pádua for both 
1
H and 
13
C. 
A 
B 
Scheme 1  
1 
2 
16 
 
The synthesis of 2 is important because it results in an analog that is identical to 
digitoxin, minus the sugar moiety. Including this analog in the wound closure assay (Chapter 
Three) provides valuable information about the way in which cardiac glycosides inhibit cell 
migration.  
2C. Synthesis and characterization of elimination aglycone side product 
 Analogs 4a and 4b were at first unintentionally synthesized as side products of the 
deglycosylation reaction in an attempt to synthesize 2 under reaction conditions A in scheme 2.  
 
They appeared as one spot on thin layer chromatography, and they were separated from the 
reaction mixture by column chromatography. At the time, I thought that I was likely separating 
product 2 from the reaction mixture. However, characterization by 
1
H and 
13
C NMR 
chromatography revealed that the product I purified was not digitoxigenin. The 
13
C NMR 
showed four downstream peaks that did not match the predicted chemical shifts for 2. These 
peaks were in the typical range for alkene carbons at 154.6, 138.5, 129.9, and 116.5 δ (ppm). At 
Scheme 2  
1 
4a 
4b 
A 
B 
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this point, I did not know the identity of the compound I had isolated, but I had concluded that it 
was not 2.  
 It was not until reading the Pádua et al. study on the biotransformation of digitoxigenin
17 
that we realized that the substance we isolated from the deglycosylation reaction mixture must be 
a mixture of 4a and 4b. This accounted for the downstream 
13
C signals indicating the presence of 
alkenes. Upon comparison of the 
1
H and the 
13
C data to the data published by Pádua et al.,
17
 we 
were sure that the reaction product we had isolated from the reaction products was a mixture of 
4a and 4b.  
 Attempts to separate 4a and 4b, by column chromatography were unsuccessful. The Rf 
values were identical in every solvent system that was used. They could have been separated by 
using a preparative RP-HPLC system,
17 
 but that equipment was not available. For our purposes 
we decided that it would be acceptable to use a mixture of 4a and 4b in the wound closure assay 
to determine the importance of the steroid core to cell migration inhibitory activity. Additional 
4a/4b was synthesized as a side product during the synthesis of 2 under the Pádua reactions 
conditions shown in B of Scheme 2. 
2D. Synthesis and characterization of 20,22-dihydrodigitoxin 
 20,22-dihydrodigitoxin 3 was synthesized by reducing the double bond between C20 and 
C22 of digitoxin. The starting material, 1, was added to 10% Pd on carbon dissolved in 
methanol. The solution in the round bottom flask was sealed with a rubber septum and flushed 
first with nitrogen and then with hydrogen gas. The solution was treated with excess hydrogen 
gas overnight.  The reaction mixture was purified by filtering through celite to remove the 
carbon. Thin layer chromatography showed only one compound, with an Rf value very close to 
18 
 
that of the starting material. Complete conversion of 1 to 3 was assumed, so no further 
purification was performed.   
 
 The product 3 was characterized by 
1
H and 
13
C NMR chromatography, which confirmed 
complete conversion of  1 to 3. In the 
13
C NMR of 1, there is a peak with a chemical shift of 
117.8 δ (ppm) marking the presence of C22. In the 
13
C NMR of 3, this peak at 117.8 δ (ppm) is 
absent, indicating that the reduction of double bond between C20 and C22 has occurred. 
 3 is an important analog for providing information about role of the butenolide moiety in 
the inhibition of cell migration by cardiac glycosides. The reduction of the double bond changes 
the stereochemistry of the lactone ring, which could potentially affect the bond between 3 and its 
target protein.  
 
2E. Synthesis and characterization of 20,22-dihydrodigitoxigenin 
 20,22-dihydrodigitoxigenin was synthesized in two steps under the reaction conditions 
shown in Scheme 4. The C20, C22 double bond in 2 proved to be significantly more difficult to 
Scheme 3  
1 3 
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reduce than the same bond in 1. Several unsuccessful hydrogenation attempts were made using 
the same 10% Pd on carbon as in Scheme 3. Then, we switched to 20% palladium hydroxide on 
carbon, and the reaction was successful. The product 5 was characterized by 
1
H and 
13
C NMR 
chromatography and the reduction of the C20, C22 double bond was confirmed by the absence of 
the peak at 117.8 δ (ppm).  
 Since both the sugar moiety and the butenolide moiety were modified in this synthesis, a 
wound closure assay on 5 would not provide as valuable information about the structure-function 
relationship between digitoxin and cell migration inhibitory activity.  It is better to modify only 
one moiety at a time, to see how that specific moiety affects cell migration inhibition. So after an 
error occurred during the first wound closure assay of 5, a second assay has not yet been 
completed.  
 
 
 
 
Scheme 4  
5 2 
1 
20 
 
2F. Attempted synthesis of open butenolide ring analog 
 The wound closure assay data from 3 gives some information about the butenolide ring 
and its effects on cell migration. However, a complete opening of the butenolide ring would 
allow for a clearer picture of its importance in the cell migration inhibition process.  
 The first method we used to try opening the butenolide ring was ozonolysis of digitoxin. 
Several unsuccessful ozonolysis attempts were made, using both methanol and methylchloride as 
solvents. In several attempts, the spectroscopy showed that the reaction had not gone to 
completion and only starting material present. Then in a few attempts, a product was formed, but 
the spectroscopy suggested that it was not the product we were looking for.  
 Ring opening aminolysis was also used to try to open the butenolide ring. We used the 
procedure described by Liu for opening lactone rings with benzylamine and sodium 2-
ethylhexanoate, which acts as a base and a catalyst.
18
  However this reaction was unsuccessful 
when performed on both 1 and 2. In all attempts, there was no addition of the benzylamine, 
which would have been visible under UV light and also would have been noticeable in the 
spectroscopy.  
 We would still like to have an analog of digitoxin where the butenolide ring has been 
opened. We are hoping that we will be able to reduce the lactone of 3 or 5 to a diol by treating 
with DIBAL or lithium aluminum hydride. 
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Chapter Three: Inhibition of Cell Migration, Measured by a Wound Closure Assay 
3A. Description of cell line 
 MDA-MB-231 human breast carcinoma cells were obtained from the American Tissue 
Culture Collection (ATCC) or Kam C. Yeung of the University of Toledo. This particular cell 
line is one of the most commonly used breast cancer cell lines in research labs across the 
country. The MDA-MB-231 cell line is well studied, characterized, and cited in the literature.
19 
 
It was originally taken from a 51 year-old, Caucasian woman in October of 1973 at the M. D. 
Anderson Cancer Center.
20
  The malignant MDA-MB-231 carcinoma cells were taken from a 
pleural effusion that matched the primary tumor of her breast.
20
 Systemic treatment for the 
patient included fluorouracil and prednisone, while chemotherapeutic treatment was a 
combination of cyclophosphamide, adriamycin, amethopterin. The cells were resistant to both 
systemic and chemotherapeutic treatment at the time and the patient died several months later.
20
  
MDA-MD-231 cells have a mean chromosome number of 64, making them nearly triploid.
21 
 
They also have several identifying  markers and they are capable of forming tumors in nude 
mice.
21
  
 The MDA-MD-231 cell line has several characteristics that make it a good choice for the 
wound closure and cell migration assay. First of all, this cell line grows fairly rapidly. This 
helped to expedite the process of growing the cells from frozen samples, culturing the cells, and 
subculturing the cells to create different passages. This also allows for efficient use of materials 
and growth medium, as compared to cell lines that would take weeks to culture into a confluent 
group and use up considerably more resources. A 1:10 dilution of MDA-MB-231 cells takes 
approximately four to five days to reach confluence,
21
 which was optimal for this research.  
22 
 
Fig 3.  MDA-MB-231 cell growth properties. 
This image depicts the confluent monolayer growth 
that is typical of the MDA-MB-132 cell line 
 The growth properties of the MDA-MB-231 carcinoma cell line are essential for the cell 
migration assay used in our research. Some cell lines used in cancer research do not have this 
monolayer growth pattern and tend to grow in masses or clumps that do not adhere well to a 
surface. However, MDA-MB-231 cells grow into a confluent monolayer on glass and treated 
plates as shown in Figure 3. Formation of a 
monolayer with uniform cell growth allows for 
the wound to close evenly on all sides during 
the wound closure assay to determine cell 
migration. If the cells did not adhere well to 
the plate, they could easily be dislodged 
during the process of moving the plates from 
the incubator, to the laminar flow cabinet, to 
the microscope. This would of course 
completely disrupt the uniform wound closure and cell migration.  
 The MDA-MB-231 cell line also falls under the category of “triple-negative” cancer 
cells.
22 
 Triple negative breast cancer cells are defined by their lack of estrogen receptors, 
progesterone receptors, and human epidermal growth factor receptor 2 (HER2).
23, 24 
 Only about 
10-17% of breast carcinomas can be categorized as triple negative.
24
 Triple negative cancer cell 
lines such as MDA-MB-231 are more aggressive and are not susceptible to some of the typical 
systemic therapy options that target the estrogen receptor or HER2.
24
 Instead, chemotherapy 
remains the only option for the treatment of triple negative cancers. This makes the study of 
triple negative cell lines and their interactions with small molecules relevant from a medicinal, 
pharmacological, and scientific standpoint.   
23 
 
Fig 4. MDA-MB-231 cell growth and proliferation. A.) The MDA-MB-231 cells are first plated  
at a lower density in preparation for the wound closure/cell migration assay. B.) As the cells are fed, 
they grow and proliferate until they become a confluent monolayer, ready for the assay. 
3B. Procedure for screening of small molecule libraries for antimigratory activity 
The wound closure assay used to screen libraries of small molecules was developed by 
the Fenteany lab,
25
 and the same procedures were essentially used in this screening.
26
 The small 
molecule libraries were obtained from Chembridge and AnalytiCon. The screening was 
conducted using BT-20, T47D, MDA-MB-231, MDA-MB-435, 4T1, and MDCK cells, which 
were obtained from either the ATCC or the Yeung lab. The cells were shipped and stored frozen 
at -80°C in cryovials. Cells were grown in a tissue culture incubator at 37°C with 5% CO2 in 
minimum essential medium with additional Dulbecco’s modified Eagle medium containing 10% 
fetal bovine serum (FBS). The medium was changed every two days. Cells were plated on 24-
well tissue culture-treated plates. When the cells reached confluence as depicted in Figure 4, the 
medium was changed a final time and the experiment was started the next day. 
 
 
 
A B 
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Fig 5.  Wounding for Cell Migration Screening Assay. 
This image depicts size and shape of a typical wounded 
monolayer of MDA-MB-231 cells at 0 hour of the cell 
migration inhibition screening assay.  
The carrier solvent for each compound was DMSO, used at less than 1%.  Cells were 
treated with 100 µM of each compound or 1% DMSO alone. The compounds to be screened or 
the 1% DMSO control were mixed with fresh medium and added to the cells as a medium 
change. The cells were exposed to the compounds or 1% DMSO for 30 minutes before the cell 
monolayers were scratched with a micropipette tip, creating wounds of about 0.5–1.0 mm2 in 
area as in Fig 5. After the 30 minute 
incubation, the cells were observed 
for wound closure every 12 hours for 
the next 72 hours with an inverted 
microscope. At each observation, the 
wounds were deemed either open or 
closed. Wounds that were still open 
after the control 1% DMSO wounds 
had closed indicated that the 
compounds had antimigratory 
activity. However, it had to be verified that the inhibition of wound closure was not due to 
cytotoxicity. As has often been quoted, “dead cells don’t move.”  The trypan blue dye exclusion 
assay was used to determine cytotoxicity.
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Several members of the cardiac glycoside group of natural products were among the 
small molecules that displayed antimigratory activity in the screening of the two libraries. They 
were deemed interesting choices for further investigation because, as explained in the 
introduction, they have already been well studied as inhibitors of the protein Na,K-ATPase, but 
not as inhibitors of cell migration. Analogs of digitoxin and ouabain were synthesized (see 
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Chapter 2) and used for additional antimigratory wound closure assays to further analyze the 
antimigratory activities of these cardiac glycosides. 
 
3C. Procedure for conducting wound closure assay with a target molecule 
For the assay of digitoxin and its analogues, the cell line used was the previously 
described MDA-MB-231 human breast carcinoma cells. Each wound closure assay was done in 
triplicate, with three different passages. In order to achieve these different passages, the cells had 
to be subcultured. The cells were removed from the  -80° freezer and thawed by rolling the 
cryovial between one’s hands. The thawed cells in storage medium were then transferred to a 
conical tube containing growth medium and centrifuged at 1000rpm for five minutes. The 
supernatant was removed by aspiration and the remaining mass of cells was resuspended in 
15mL of new growth medium. The cell suspension was then transferred and divided between 
three tissue culture-treated plates and incubated at 37°C with 5% CO2. The cells were monitored 
daily and the growth medium was changed every 24 to 48 hours.  
When the MDA-MB-231 cells reached confluence on the tissue culture plates, they were 
passaged, or “split.” The first step in splitting the cells was to remove the growth medium. This 
was done by aspiration. A phosphate buffered saline (PBS) solution was used to wash or rinse 
the plates three times in succession. This ensured the removal of any dead cells, cell wastes, 
spent medium, or serum in the medium which inhibits trypsin. After washing the cells, they were 
treated with trypsin, a protease that cleaves the bonds holding the cells to the surface of the 
treated culture plate. After incubating the cells with trypsin for 15 minutes, the cells were no 
longer attached to the plate so an equal volume of growth medium was added to quench the 
trypsin reaction. These suspended cells were transferred to a conical tube and centrifuged at 
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1000rpm for five minutes. The supernatant was removed and the cells were resuspended in 
growth medium. The new solution of cells was then plated onto treated tissue culture plates at 
different concentrations in order to create new passages that would take different amount of time 
to reach confluence. After each of these new passages was split several times in the same 
manner, they were split a final time. In this final split, they were diluted and plated in 96 well 
plates, with 100μL in each well. These cells took about four days to reach confluence, during 
which the medium was changed regularly. Once confluence was achieved in the final passage, 
the cells were ready for the wound closure assay. 
The glycoside analog to be tested was diluted with four-fold serial dilution, with 
concentrations ranging from 1mM to 15nM. Once the glycoside solution was diluted in DMSO 
and mixed with fresh medium, it was added to the cell culture. The MDA-MB-231 cells were 
allowed to incubate with the glycoside solution for 30 minutes. After the incubation, the 
monolayer of MDA-MB-231 cells was wounded using micropipette tip to produce a small oval 
shape wound of about 0.5 to 1.0 mm
2
 in area. During this assay, an initial picture of the wound 
was taken, and then taken again every three hours, for 24 hours, or as long as it took for the 
control wounds to close entirely.  
Fig 6. Comparison of wound closure in cells treated with glycoside and cells treated with DMSO control.  The pictures of the 
wounded cell monolayers were taken using an inverted microscope and camera attached to a computer. The top panel of pictures 
represents one of the nine wells containing 1mM DMSO, and how the cells migrated to completely close the wound by 33 hours. 
The bottom panel of pictures represents one of the nine wells containing 250μM digitoxin, where the percent closure of the initial 
wound is significantly less than that of the DMSO control. This indicates inhibition of cell migration by digitoxin.  
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Under ideal timing, the final set of pictures was taken just before the DMSO control wounds 
were completely closed. This allowed for the most accurate measurement of percent closure of 
the wounds treated with the glycoside compared to the DMSO control.  
 The cardiac glycosides were tested at each concentration in triplicate and using three 
different passages of MDA-MB-231 cells. Each passage of cells was on its own 96 well plate. 
This gave a total of nine trials for each concentration of the target glycoside analog. After the 
assay was complete, the digital images were transferred to a PC to be processed. The NIH 
software ImageJ (free download at http://rsb.info.nih.gov/ij/) was used to trace the perimeter of 
the wound in each picture. The area enclosed by this tracing was computed in units of pixels.  
Once the areas of the wounds had been measured at each time interval, it was possible to 
calculate the percent closure by comparing the area of the wound at each time interval to the 
initial area at hour 0. These values were compared to the percent closure of the wounds treated 
with DMSO control. Minimum inhibitory values (MIC) and IC50 values were calculated with 
GraphPad Prism software from concentration–response data.  
 
3D. Relating results of antimigratory activities for digitoxin and analogs to structure 
 In the screening of the small molecule libraries, the cardiac glycosides ouabain, digitoxin, 
and oleandrin all displayed antimigratory activity. So it was expected that the digitoxin analogs 
synthesized would all have at least some antimigratory activity. The antimigratory activities are 
expressed with two different values. The first is the minimum inhibitory concentration or MIC. 
This is the lowest concentration of the cardiac glycoside that still displays antimigratory activity. 
The second value is the half maximal inhibitory concentration, or the IC50. This is the 
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concentration of cardiac glycoside that reduces cell migratory activity by half. Both the MIC and 
the IC50 for digitoxin and its analogs are reported in Table 1.   
Cardiac Glycosides Wound Closure Assay Na
+
/K
+
 – ATPase  
Inhibition Assay 
Compound Structure Percent Inhibition  
(at highest concentration) 
MIC 
(μM) 
IC50 
(μM) 
IC50  
(μM) 
1 
 
51.5%  (250 μM) 0.015 0.046 0.005 
2 
 
31.8%  (250 μM) 0.24 0.260 0.097 
3 
 
36.8%  (250 μM) 1.0 2.15 0.691 
4a and 4b 43.2%  (62.5 μM) 9.2 10.8 3.2 
Table 1.  Measured activities for cell migration inhibition and Na
+
/K
+
-ATPase inhibition.  These values were 
determined by wound closure assays and Na
+
/K
+
-ATPase inhibition assays.  
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 Digitoxin 1 proved to have greater antimigratory activity than any of the synthesized 
analogs. 1 inhibited wound closure with MIC and IC50 values that were each on a nanomolar 
scale at 15 nM and 46 nM respectively. Activity on a nanomolar scale is a characteristic common 
to many of the most successful pharmaceutical drugs. It allows the drug to be used at low 
dosages that do not come near its minimum lethal concentration (MLC). For digitoxin, the trypan 
blue stain was performed at the conclusion of each wound closure assay to determine 
cytotoxicity. However, it was a rather subjective test, which made it difficult to determine an 
exact MLC value with any certainty. A large MLC and a small MIC is optimal for potential 
drugs, which are rated using a therapeutic index (MLC/MIC). However, without an MLC for 
digitoxin and its analogs, the calculation of therapeutic indices was not possible.  
 MIC and IC50 values provide information about the activity of a compound at lower 
concentrations. The nanomolar MIC and IC50 values for 1 show that it has the strongest 
antimigratory activity in terms of its ability to inhibit cell migration at low concentrations. 
However, 1 also has the strongest antimigratory activity as a measurement of percent inhibition 
at the highest concentrations. At 250 μM, 1 had 51.5% inhibition of cell migration, measured by 
the wound closure assay. This is a significantly greater value than any of the digitoxin analogs 
that were tested.  
 The only structural difference between 1 and 2 is the presence or absence of the three 
sugars. So the antimigratory activities of 2 provide information on the importance of the sugar 
moiety to the biological activity of cardiac glycosides. However, out of the digitoxin analogs 
tested, 2 had the smallest drop in antimigratory activity, with MIC and IC50 values still at the 
upper end of the nanomolar scale at 240 nM and 260 nM respectively.  The percent inhibition at 
a concentration of 250 μM also drops from 51.5% in 1 to 31.8% in 2.  
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 The wound closure assays conducted with 3 provide information about the butenolide 
ring on cardiac glycosides and its role in the inhibition of cell migration. The reduction of the 
C20-C22 double bond in the lactone ring of digitoxin is the only structural difference between 
compounds 3 and 1, and it resulted in a decrease in antimigratory activity. The wound closure 
assay for 2 resulted in the MIC and IC50 values for cell migration inhibition dropping out of the 
nanomolar range and into the micromolar range at 1.0 μM and 2.15 μM. Although the reduction 
of the C20-C22 double bond alters the structure of the butenolide ring and introduces a new 
chirality center, it does not entirely compromise the conformational integrity of the lactone. It 
would be very interesting to see if a complete opening of the butenolide ring would result in a 
much more pronounced decrease in antimigratory activity. Unfortunately, the synthesis of this 
type of analog has proved challenging and is still in progress as described in Chapter 2.  
 Compounds 4a and 4b had the lowest antimigratory activities among the digitoxin 
analogs tested in the wound closure assay. The measured MIC value was 9.2 μM and the IC50 
value was 10.8 μM. Two out of the three fundamental structures of cardiac glycosides described 
in Chapter 1, have been compromised in 4a/4b. The sugars have been removed from C3 and the 
curved shape of the steroid core has been altered by an elimination reaction. Direct comparison 
of 4a/4b to 1 would leave uncertainty as to whether the differences in antimigratory activities are 
as a result of the glycolysis or the elimination reaction that occurred in rings C and D. In order to 
determine the loss of antimigratory activity as a direct result of the changes to the steroid core, it 
is necessary to compare the MIC and IC50 values of 2 and 4a/4b. As shown in Table 1, the IC50 
value increased from very significantly from 0.260 μM in 2 to 10.8 μM in 4a/4b. Although 
4a/4b displayed the lowest antimigratory activity as expressed by MIC and IC50, they did have a 
43.2% inhibition at the highest concentration (62.5 μM). This shows that at higher concentration, 
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4a/4b have greater antimigratory activity than 2 and 3, which have percent inhibitions of 31.8% 
and 36.8% respectively at a concentration of 250 μM. Again, biological activity at higher 
concentrations is not as important pharmacologically because of concern about approaching the 
MLC, but for our purposes it is worth noting.  
 
 
3E. Correlation between antimigratory activities and Na
+
/K
+
 - ATPase inhibition for 
digitoxin and analogs  
 After digitoxin and its analogs were tested for antimigratory activity with the wound 
closure assay, Na
+
/K
+
 -ATPase inhibition assays were conducted to measure the capacity of 
these molecules to inhibit the enzymatic activity of the Na
+
/K
+
 -ATPase protein. These assays 
were conducted by Anniefer Magpusao of the Peczuh Group at the University of Connecticut. 
Figure 7 provides an overview of the experimental procedure for the Na
+
/K
+
 -ATPase inhibition 
assay performed by Magpusao.  
 The Na
+
/K
+
 -ATPase enzyme actively exchanges sodium and potassium across the 
plasma membrane against their concentration gradients.  In order to provide energy for the ion 
exchange, the Na
+
/K
+
 -ATPase hydrolyzes ATP into APD and phosphate. In this Na
+
/K
+
 -
ATPase inhibition assay, the concentration of the newly generated phosphate is used as a direct 
measurement of the activity of the Na
+
/K
+
 -ATPase pump. The phosphate is measured using 
Taussky-Shorr reagent (1% w/v ammonium molybdate, 2.7% v/v sulfuric acid, and 5% w/v 
ferrous sulfate hexahydrate).
27, 28 
 The ammonium molybdate in Taussky-Shorr reagent reacts 
with the inorganic phosphate to form PMO12O40 
3-
, which is in turn reduced by the ferrous sulfate 
hexahydrate to form PMO12O40 
7-
, a blue colored ion that absorbs light at a wavelength of 
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660nm.
28
 This absorbance is directly proportional to the concentration of phosphate in the 
solution, which is in turn proportional to the enzymatic activity of Na
+
/K
+
 -ATPase pump.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treating the Na
+
/K
+
 -ATPase solution with digitoxin and analogs effectively inhibited 
Na
+
/K
+
 -ATPase and resulted in decreased enzymatic activity. IC50 values were generated for 
each of these compounds and they are included in Table 1.  
 Data from the wound closure assays and the Na
+
/K
+
 -ATPase inhibition assays were 
compared to look for a correlation between the antimigratory activity and the Na
+
/K
+
 -ATPase 
Fig 7. Overview of Na
+
/K
+
 -ATPase inhibition assay. 
Digitoxin or analog was added to a Na
+
/K
+
 -ATPase 
solution in Tris Buffer (pH 7.8) and incubated with ATP 
for 90 minutes. The reaction was quenched with TCA. 
Tasusky-Shorr reagent was added to visualize the 
concentration of inorganic phosphate. After 15 minutes, 
the absorbance was read at 660 nm.  
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inhibition activity of the cardiac glycosides digitoxin and its analogs. Figure 8 illustrates how 
these data provide support for a positive correlation between these two activities.  
 
 
 
 
Digitoxin 1, the most potent inhibitor of  Na
+
/K
+
 -ATPase, was also the most potent inhibitor of 
cell migration. 2 was second strongest inhibitor of both Na
+
/K
+
 -ATPase and cell migration. This 
trend continued for 3 and 4a/4b, with the IC50 values increasing proportionally for each type of 
activity. Additionally, none of the cardiac glycosides inhibited cell migration below the 
concentration at which they inhibited the Na
+
/K
+
 -ATPase pump.  The correlation was observed 
by Magpusao when the same assays were done with the cardiac glycoside ouabain and its 
analogs as part of current research that is not yet published.  
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2.15 
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Fig 8. Correlating antimigratory activity with Na
+
 / K
+
 - ATPase inhibitory activity in digitoxin 
and its analogs. The cardiac glycoside analogs that had lower IC50 concentrations for inhibiting cell 
migration also had lower IC50 concentrations for inhibiting the Na
+
/K
+
 - ATPase enzyme. As cell 
migration inhibition decreased from analog to analog, Na
+
/K
+
 - ATPase inhibition also decreased. 
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Chapter Four: Discussion 
A. Summary of Results 
 The IC50 values of the wound closure data in Table 1 clearly show that digitoxin (1) is 
the most potent inhibitor of cell migration. When the sugars were cleaved from digitoxin to give 
digitoxigenin (2), there was a decrease in cell migration inhibition, but it still had an IC50 in the 
nanomolar range. A much more significant decrease in cell migration inhibition came when the 
the C20-C22 double bond in the butenolide ring was reduced in the analog 20,22-
dihydrodigitoxin (3). Then the most drastic decrease in cell migration inhibition was for the 
elimination side product analog (4a/4b), where the structure of the steroid core was 
compromised. This trend was exactly the same for the Na
+
/K
+
 -ATPase inhibition assay. Figure 
8 presents this trend in a way that is easy to see. These results provide information as to which of 
the three moieties of cardiac glycosides is most important for interaction with the Na
+
/K
+
 -
ATPase. The sugar is least important, flowed by the butenolide ring, and then the steroid core is 
the moiety that is most crucial in the interaction between cardiac glycosides and the Na
+
/K
+
 -
ATPase protein.  
 The strong correlation between the IC50 values of the cell migration assay and the Na
+
/K
+
 
-ATPase inhibition assay is another key result of this research. This correlation strongly suggest 
that the cardiac glycoside digitoxin and its analogs are inhibiting cell migration through their 
inhibition of the Na
+
/K
+
 -ATPase protein. This conclusion is further supported by the result that 
no glycoside analog inhibited cell migration at a lower concentration than was necessary to 
inhibit the Na
+
/K
+
 -ATPase pump.  
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4B. Perspectives and Conclusions 
 Currently there are three main modes of action proposed for the observed effects f the 
inhibition of the Na
+
/K
+
 -ATPase by cardiac glycosides. The classical Na
+
 lag hypothesis 
explains the positive inotropic effect of cardiac glycosides on cardiac monocytes.
29 
 In this 
mechanism, inhibition of Na
+
/K
+
 -ATPase decreases the sodium ion concentration inside the 
cells, which then leads to an increase in intracellular calcium concentration through the reverse 
mode Na
+
/Ca
2+
 exchanger (NCX). This increase in calcium concentration eventually leads to 
muscle contraction.
29 
 The second mechanism of action proposes the existence of Na
+
/K
+
 -
ATPase signalosome.
30
  In this mechanism, it was proposed that certain populations of Na
+
/K
+
 -
ATPase exist in a caveolae along with a number of proteins such as Src,
31 
 PLC,
32
 and P13K and 
forms a signalosome. Binding of cardiac glycosides in the Na
+
/K
+
 -ATPase in this signalosome 
activates these proteins and triggers various signal transduction cascades leading to the activation 
of MAPK (ERK 1/2) pathway. Some of the signaling events were reported to occur even at 
concentrations of cardiac glycosides that are too low to affect the ion homeostasis, thus 
suggesting that the binding of cardiac glycosides to Na
+
/K
+
 -ATPase can initiate a signaling 
cascade without affecting the pumping action of this ion transporter. The third method of action 
was proposed in 2008, which calls into action the energy-sensing kinase AMPK.
33
 Since Na
+
/K
+
 
-ATPase is responsible for the consumption of approximately 40% of the cellular ATP, its 
inhibition greatly affects the total AMP/ATP ratio in the cell. This in turn is a signal for the 
activation of AMPK. Soltoff and Hedden showed that inhibition of Na
+
/K
+
 -ATPase blocks the 
phosphorylation of AMPK, which inturn leads to the activation of ERK 1/2.
33
 
 These different mechanism were observed using different experimental conditions and 
different cell lines. In our study, we used triple negative MDA-MB-231 human breast cancer 
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cells and looked into the correlation of IC50 values of different analogs of digitoxin with respect 
to both cell migration and Na
+
/K
+
 -ATPase inhibition assays. We found that the IC50 values for 
digitoxin and its analogs for the cell migration assay correlate very well with the IC50 values for 
the Na
+
/K
+
 -ATPase inhibition assay. Also, we did not observe inhibition of cell migration below 
the concentration of cardiac glycoside that inhibits Na
+
/K
+
 -ATPase. Based on these results, it is 
more likely that the mechanism of the inhibition of cell migration and its analogs involves the 
perturbation of the Na
+
, K
+
, and Ca
2+
 ion homeostasis caused by the inhibition of Na
+
/K
+
 -
ATPase. The next interesting step then to explore for project would be to evaluate how digitoxin, 
its analogs, and other cardiac glycosides and other Na
+
/K
+
 -ATPase inhibitors affect the 
concentration of these three key ions. Correlating this with the observed inhibition of cell 
migration might provide further information on how cardiac glycosides inhibit cell migration.  
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